- Avicanna (AVCN) has signed a new sub-license agreement with VB Brands California LLC and Player Holdings LLC
- The sub-license agreement allows Avicanna to commercialize its Viola-branded products in the United Kingdom territory
- In UK, the company has signed a sub-licensing agreement with Vertical Pharma Resources Limited T/A IPS Pharma
- Avicanna is a commercial-stage international biopharmaceutical company
- Avicanna Inc. (AVCN) opened trading at C$0.42 per share
Avicanna (AVCN) has signed a new sub-license agreement with VB Brands California LLC and Player Holdings LLC.
The sub-license agreement is to commercialize its Viola-branded products in the United Kingdom. In the UK, the company has signed a sub-licensing agreement with Vertical Pharma Resources Limited T/A IPS Pharma for the manufacturing and distribution of the products.
Starting late Q1 2023, Viola’s products will be available to patients in the UK through this exclusive licensing agreement.
IPS Pharma is a local pharmaceutical distribution company. It has more than 20 years of experience with unlicensed medicines to support the launch of the product offerings. The company will manufacture initial products in the UK under GMP guidelines. It will distribute the products through IPS Pharma’s existing network of pharmacies via medical prescription under the Special Access Program.
The initial products offered in the UK will include proprietary formulations of vaporizers in THC-dominant and balanced CBD: THC ratios. It will be supported by medical education and training.
The UK government legalized the use of cannabis in 2018. Medical cannabis can be prescribed by specialists as an unlicensed medicine in the UK called CBPM (cannabis-based product for medicinal use).
Avicanna is a commercial-stage international biopharmaceutical company. It focuses on the advancement and commercialization of evidence-based cannabinoid-based products for the global medical and pharmaceutical market segments.
Avicanna Inc. (AVCN) opened trading at C$0.42 per share.
